Search Results

You are looking at 101 - 110 of 299 items for :

Clear All
Full access

/Refractory Multiple Myeloma Beth Faiman, PhD, MSN, APRN-BC, AOCN, Cleveland Clinic Taussig Cancer Institute Clinical Updates and Issues: Advanced Non–Small Cell Lung Cancer Tracy Ruegg, MSN, CNP, AOCN, The Ohio State University Comprehensive Cancer Center

Full access

. A virtual learning platform for multiple myeloma is expected to launch in 2015. For more information about the NCCN 3D Virtual mCRC Simulator Learning Platform, visit NCCN.org . Free NCCN Pocket Guidelines Available for Antiemesis and

Full access

Severe Hypertriglyceridemia and Acute Pancreatitis Expiration Date: 1/11/14 NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2013 Expiration Date: 1/11/14 Modern Staging of Small Cell Lung Cancer Expiration Date: 1/11/14 CASE REPORT

Full access

leukemia (CML), multiple myeloma, triple-negative breast cancer, hormone-sensitive breast cancer, squamous cell carcinoma of the lung, advanced adenocarcinoma of the lung, colorectal cancer, prostate cancer, melanoma, and kidney cancer. Each webinar will be

Full access

, Chronic Myelogenous Leukemia, Malignant Pleural Mesothelioma, Melanoma, Multiple Myeloma, and Lung Cancer Screening. Additional NCCN Guidelines for Patients will be available throughout 2013. Printed copies of the NCCN Guidelines for Patients: Caring for

Full access

Robert W. Carlson

well as multiple myeloma, acute lymphoblastic leukemia, and melanoma. Additionally, 3 brand new NCCN Guidelines were presented: Cancer in People Living with HIV, Management of Immunotherapy-Related Toxicity, and Uveal Melanoma. NCCN experts also

Full access

-small cell lung, pancreatic, and prostate cancers; melanoma; chronic myelogenous leukemia; lung cancer screening; malignant pleural mesothelioma; multiple myeloma; and caring for adolescents and young adults (AYA). NCCN Guidelines and Compendium Updated

Full access

Lainie Martin and Russell J. Schilder

refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients . Blood 2001 ; 98 : 492 – 494 . 33. Singhal S Mehta J Desikan R . Antitumor activity of thalidomide in

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Christine Gasparetto, Francisco Hernandez-Ilizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, Furhan Yunus, Rashmi Kumar and Dorothy A. Shead

myeloma and systemic light chain amyloidosis. The NCCN Guidelines for WM/LPL include diagnosis, workup, and management. These NCCN Guidelines Insights highlight important updates/changes specific to the management of WM/LPL in the NCCN Guidelines. These

Full access

Richard L. Theriault

mice . Int J Cancer 1998 ; 77 : 279 – 285 . 39 Dallas SL Garrett R Oyajobi BO . Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease . Blood 1999 ; 93 : 1697 – 1706 . 40